Genetic variability within the cholesterol lowering pathway and the effectiveness of statins in reducing the risk of MI
about
The UBIAD1 prenyltransferase links menaquinone-4 [corrected] synthesis to cholesterol metabolic enzymesApplication of routine electronic health record databases for pharmacogenetic researchEvaluation of the effect of genetic variation on the relationship between statins, cardiovascular disease and cancerPatient healthcare trajectory. An essential monitoring tool: a systematic review.Preliminary evidence for an association between LRP-1 genotype and body mass index in humans.Dietary Fat Intake Modifies the Effect of a Common Variant in the LIPC Gene on Changes in Serum Lipid Concentrations during a Long-Term Weight-Loss Intervention Trial.Low density lipoprotein receptor related protein 1 and 6 gene variants and ischaemic stroke riskGenetic contribution of SCARB1 variants to lipid traits in African Blacks: a candidate gene association study.Gender and single nucleotide polymorphisms in MTHFR, BHMT, SPTLC1, CRBP2, CETP, and SCARB1 are significant predictors of plasma homocysteine normalized by RBC folate in healthy adults.Genetics of Dyslipidemia.Pharmacogenomics of lipid-lowering therapies.To replicate or not to replicate: the case of pharmacogenetic studies: Establishing validity of pharmacogenomic findings: from replication to triangulation.Bridging the gap for lipid lowering therapy: plaque regression, coronary computed tomographic angiography, and imaging-guided personalized medicine.Seventeen years of statin pharmacogenetics: a systematic review.Associations between long-term exposure to PM2.5 component species and blood DNA methylation age in the elderly: The VA normative aging study.Clinical relevance of peroxisome proliferator-activated receptor-γ gene polymorphisms with sepsis.
P2860
Q24304189-12C5A81F-612F-41D4-8336-528553D03BC0Q26864747-453568C4-6ABD-452F-B8BA-B58A420D88C8Q27026358-3EE420CC-F402-4CDE-8F63-483294B30BF7Q30234772-EE5D009E-05AF-4194-BC43-221C1A5E862EQ31048831-451EB8F8-A0D9-47CA-A093-0A662802385AQ35640027-1DCBD477-FB02-4759-994A-069F13EEAA32Q35832752-9C042B1F-725A-4F8F-9944-9A723527BE37Q35840145-756E6AEA-DF13-4A54-BF0E-C9B3ADDDBBFFQ36160345-DDB9AF30-C7ED-42B7-87C8-DDE4911C6382Q37021351-07553151-E143-4EBB-96DA-8001F38F7B15Q38112823-036ACCCF-75C8-4DD7-A32C-185D822A8865Q38130427-A4CFDD50-960B-4124-BDB5-51442B83DDFEQ38665677-15453454-E238-46BC-8492-8265AAEB7C57Q38670109-A6977A76-2EB5-4A7B-A3B6-58FDC1FA4583Q46405421-BB4CF7F0-535A-4E3F-8B00-B51799CC9931Q48152839-4A0EEF58-5202-4302-B911-E19AD7A6A076
P2860
Genetic variability within the cholesterol lowering pathway and the effectiveness of statins in reducing the risk of MI
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Genetic variability within the ...... ins in reducing the risk of MI
@ast
Genetic variability within the ...... ins in reducing the risk of MI
@en
type
label
Genetic variability within the ...... ins in reducing the risk of MI
@ast
Genetic variability within the ...... ins in reducing the risk of MI
@en
prefLabel
Genetic variability within the ...... ins in reducing the risk of MI
@ast
Genetic variability within the ...... ins in reducing the risk of MI
@en
P2093
P2860
P1433
P1476
Genetic variability within the ...... ins in reducing the risk of MI
@en
P2093
Anke-Hilse Maitland-van der Zee
Anthonius de Boer
Bas J M Peters
Bruno H Ch Stricker
Helmi Pett
Josh C Bis
Kerri L Wiggins
Nicole L Glazer
Olaf H Klungel
P2860
P304
P356
10.1016/J.ATHEROSCLEROSIS.2011.06.023
P577
2011-06-17T00:00:00Z